Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AMPKγ1 Program
- Development stage
- Preclinical
- Lead developer
- Korro Bio
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
The AMPKγ1 Program is a preclinical research initiative developed by Korro Bio, Inc. that utilizes its proprietary OPERA (Oligonucleotide Promoted Editing of RNA) platform. The program focuses on a GalNAc-conjugated RNA editing oligonucleotide designed to target the AMPKγ1 (AMP-activated protein kinase gamma 1) subunit. By making precise, transient single-base edits to the RNA transcript, the therapy aims to achieve allosteric activation of hepatic AMPKγ1. This mechanism is intended to restore metabolic signaling and improve liver function, with potential therapeutic applications in liver disease and longevity. As an RNA editing modality, it works by modifying RNA rather than DNA, offering a reversible and precise approach to protein modulation. The program is currently in the discovery stage.
- Other names
- Korro Bio AMPKγ1 RNA editing programOPERA AMPKγ1 program
02
Targets
PRKAG1 (AMPK gamma-1)
Beyond the preview
Go deeper on AMPKγ1 Program.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AMPKγ1 Program.